Cite
Collins GP, Eyre TA, Schmitz-Rohmer D, et al. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. Hemasphere. 2021;5(11):e656doi: 10.1097/HS9.0000000000000656.
Collins, G. P., Eyre, T. A., Schmitz-Rohmer, D., Townsend, W., Popat, R., Giulino-Roth, L., Fields, P. A., Krasniqi, F., Soussain, C., Stathis, A., Andjelkovic, N., Cunningham, D., Mandic, D., Radulovic, S., Tijanic, I., Horowitz, N. A., Kurtovic, S., Schorb, E., Schmidt, C., Dimitrijević, S., & Dreyling, M. (2021). A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. HemaSphere, 5(11), e656. https://doi.org/10.1097/HS9.0000000000000656
Collins, Graham P, et al. "A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma." HemaSphere vol. 5,11 (2021): e656. doi: https://doi.org/10.1097/HS9.0000000000000656
Collins GP, Eyre TA, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, Fields PA, Krasniqi F, Soussain C, Stathis A, Andjelkovic N, Cunningham D, Mandic D, Radulovic S, Tijanic I, Horowitz NA, Kurtovic S, Schorb E, Schmidt C, Dimitrijević S, Dreyling M. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. Hemasphere. 2021 Oct 27;5(11):e656. doi: 10.1097/HS9.0000000000000656. eCollection 2021 Nov. PMID: 34901759; PMCID: PMC8660000.
Copy
Download .nbib